Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report issued on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Price Performance

AKTX stock opened at $1.03 on Tuesday. Akari Therapeutics has a twelve month low of $1.03 and a twelve month high of $4.40. The company’s 50 day moving average is $2.55 and its two-hundred day moving average is $2.87.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.